Phoenix NP Announces Availability of FDA-Approved Zepbound (tirzepatide) Through Its Telehealth Weight Management Program Across Arizona

PHOENIX, AZ - February 02, 2026 - PRESSADVANTAGE - Phoenix NP, a women-focused telehealth medical practice based in ...

Eli Lilly and Company: Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with ...

At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance ...
NBC Bay Area

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

The weekly injection is now the first drug treatment option cleared for patients with obesity and moderate-to-severe obstructive sleep apnea, or OSA, which refers to breathing interrupted during sleep ...
Brattleboro Reformer

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis ...

At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and ...